Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome

[1]  J. Bogie,et al.  Fatty acid metabolism in the progression and resolution of CNS disorders. , 2020, Advanced drug delivery reviews.

[2]  D. Centonze,et al.  Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons , 2020, Neuropathology and applied neurobiology.

[3]  D. Centonze,et al.  Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction , 2019, Haematologica.

[4]  P. Calabresi,et al.  Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease , 2019, Nature Communications.

[5]  M. Maccarrone,et al.  Proresolving Lipid Mediators: Endogenous Modulators of Oxidative Stress , 2019, Oxidative medicine and cellular longevity.

[6]  M. Maccarrone,et al.  Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  C. Serhan,et al.  Metabololipidomic profiling of functional immunoresolvent clusters and eicosanoids in mammalian tissues. , 2018, Biochemical and biophysical research communications.

[8]  C. Cotsapas,et al.  Genome‐wide association studies of multiple sclerosis , 2018, Clinical & translational immunology.

[9]  Valerio Chiurchiù,et al.  Bioactive Lipids and Chronic Inflammation: Managing the Fire Within , 2018, Front. Immunol..

[10]  M. Molinari,et al.  Resolvin D1 Halts Remote Neuroinflammation and Improves Functional Recovery after Focal Brain Damage Via ALX/FPR2 Receptor-Regulated MicroRNAs , 2018, Molecular Neurobiology.

[11]  D. Reich,et al.  Multiple Sclerosis , 2018, The New England journal of medicine.

[12]  C. Serhan,et al.  Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. , 2017, Molecular aspects of medicine.

[13]  M. Febo,et al.  Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A4 analog: Protective mechanisms and long‐term effects on neurological recovery , 2017, Brain and behavior.

[14]  Jeffrey A. Bair,et al.  Lipoxin A4 activates ALX/FPR2 Receptor to Regulate Conjunctival Goblet Cell Secretion , 2016, Mucosal Immunology.

[15]  Peng Li,et al.  Enriched Endogenous Omega-3 Fatty Acids in Mice Ameliorate Parenchymal Cell Death After Traumatic Brain Injury , 2017, Molecular Neurobiology.

[16]  Zhi-Yuan Zhang,et al.  Resolvin D1 Programs Inflammation Resolution by Increasing TGF-β Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis , 2016, The Journal of Neuroscience.

[17]  Mika Gustafsson,et al.  Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. , 2016, Cell reports.

[18]  L. Battistini,et al.  Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses , 2016, Science Translational Medicine.

[19]  J. Calixto,et al.  EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. , 2016, European journal of pharmacology.

[20]  M. Zwahlen,et al.  Refined clinical scoring in comparative EAE studies does not enhance the chance to observe statistically significant differences , 2016, European journal of immunology.

[21]  R. Ji,et al.  Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection , 2016, Journal of Neuroinflammation.

[22]  C. Serhan,et al.  Resolvin D1 Reduces Emphysema and Chronic Inflammation. , 2015, The American journal of pathology.

[23]  Moses Rodriguez,et al.  Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis* , 2015, The Journal of Biological Chemistry.

[24]  T. Denning,et al.  Harnessing Regulatory T Cells for the Treatment of Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[25]  J. Palmblad,et al.  Resolution of inflammation is altered in Alzheimer's disease , 2015, Alzheimer's & Dementia.

[26]  H. Lassmann.  Mechanisms of white matter damage in multiple sclerosis , 2014, Glia.

[27]  Novel targets in multiple sclerosis: to oxidative stress and beyond. , 2014, Current topics in medicinal chemistry.

[28]  S. Quezada,et al.  Resolution of acute inflammation bridges the gap between innate and adaptive immunity. , 2014, Blood.

[29]  C. Serhan,et al.  Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. , 2014, American journal of physiology. Cell physiology.

[30]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[31]  S. Doré,et al.  Neurovascular protection by post‐ischemic intravenous injections of the lipoxin A4 receptor agonist, BML‐111, in a rat model of ischemic stroke , 2014, Journal of neurochemistry.

[32]  A. Vanderver,et al.  Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases , 2014, The Journal of Immunology.

[33]  D. Geerts,et al.  P-glycoprotein regulates trafficking of CD8+ T cells to the brain parenchyma , 2014, Acta Neuropathologica.

[34]  Qiang Wu,et al.  Lipoxin A4 ameliorates cerebral ischaemia/reperfusion injury through upregulation of nuclear factor erythroid 2-related factor 2 , 2013, Neurological research.

[35]  Moses Rodriguez,et al.  Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics. , 2013, Journal of clinical & cellular immunology.

[36]  F. LaFerla,et al.  Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. , 2013, The American journal of pathology.

[37]  Xi-ping Chen,et al.  Lipoxin A4 attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury , 2013, Brain Research.

[38]  J. Schwab,et al.  Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial , 2013, PloS one.

[39]  Ira Tabas,et al.  Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities , 2013, Science.

[40]  C. Serhan,et al.  Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. , 2012, Blood.

[41]  Peter K. Stys,et al.  Will the real multiple sclerosis please stand up? , 2012, Nature Reviews Neuroscience.

[42]  C. Serhan,et al.  Resolvins and protectins in inflammation resolution. , 2011, Chemical reviews.

[43]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[44]  D. Ganea,et al.  Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis , 2011, Brain, Behavior, and Immunity.

[45]  H. D. de Vries,et al.  Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. , 2011, Brain : a journal of neurology.

[46]  H. D. de Vries,et al.  T lymphocytes impair P-glycoprotein function during neuroinflammation. , 2010, Journal of autoimmunity.

[47]  Jie Wang,et al.  Neuroprotective Effect of Lipoxin A4 Methyl Ester in a Rat Model of Permanent Focal Cerebral Ischemia , 2010, Journal of Molecular Neuroscience.

[48]  Jie Wang,et al.  Lipoxin A4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion , 2010, Brain Research.

[49]  A. Compston,et al.  Multiple sclerosis , 2008, The Lancet.

[50]  Charles N. Serhan,et al.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.

[51]  P. Calder.  Polyunsaturated fatty acids and inflammation. , 2005, Biochemical Society transactions.

[52]  J. Greenwood,et al.  Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  C. Serhan.  Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[54]  B. Engelhardt,et al.  The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. , 2005, Trends in immunology.

[55]  Hans Lassmann,et al.  Multiple Sclerosis Pathology: Evolution of Pathogenetic Concepts , 2005, Brain pathology.

[56]  Adriano G. Rossi,et al.  Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.

[57]  Tetsuhiro Tanaka,et al.  Modulation of interferon-induced genes by lipoxin analogue in anti-glomerular basement membrane nephritis. , 2004, Journal of the American Society of Nephrology : JASN.

[58]  J. Bousquet,et al.  Lipoxins are potential endogenous antiinflammatory mediators in asthma. , 2002, American journal of respiratory and critical care medicine.

[59]  T. Takano,et al.  Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor* , 1997, The Journal of Biological Chemistry.